- Market Realist•7 hours ago
Wall Street analysts have projected that Regeneron Pharmaceuticals’s (REGN) 2017 revenues would be ~$5.5 billion, which represents year-over-year growth of ~13.2%.
- TheStreet.com•8 hours ago
Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.
- Motley Fool•yesterday
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||43.46 - 43.84|
|52 Week Range||36.81 - 44.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.26|
|Dividend & Yield||1.66 (3.88%)|
|1y Target Est||N/A|